Wednesday, March 23, 2005

DNDN

A lot of insider buying in Dendreon lately, Directors, Officers, CEO, Cheif Scientific Officer among others. I bought some this morning at $5.70. DNDN has $3.21 cash per share, virtually no debt and a lot of good science to go along with substantial insider buying at these levels.

From Yahoo:

Dendreon Corporation is a biotechnology company focused on the discovery, development and commercialization of targeted therapies for cancer. The Company's portfolio includes product candidates to treat a range of cancers using therapeutic vaccines, monoclonal antibodies, small molecules and pro-drugs. Its most advanced product candidate is Provenge, a therapeutic vaccine for the treatment of prostate cancer. Provenge is being evaluated under a pivotal, randomized, double blind, placebo-controlled Phase III clinical trial in men with androgen independent prostate cancer whose cancer has a Gleason score of seven and less. Dendreon's preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease and pro-drug product candidates for the treatment of cancer. In July 2003, Dendreon completed its acquisition of Corvas International, Inc.

4 comments:

Ross said...

Allan,

For what it is worth, DNDN looks like a dog with fleas. I hardly call a few thousand dollar investments significant, rather, it was probably a knee jerk reaction to the continued bad news. The CFO by the way, exercised options at 91 cents per share on 3/18.

Crappy chart, crappy selling, crappy effort by the insiders and most important, crappy company. Only the 2P's (plumbers and proctologists) make money in crap.

$3.21 a share in cash? Does this include include their crappy inventory too?

How can you short term trade this one? The old Peter Lynch about catching a falling knife applies here.

You have had many other good picks to tell us about. This may not be your best.

Warm Regards,

Ross

ilene said...

Hi, Ross,

Besides the chart, do you dislike dndn based on the prospects of their drug, Provenge (an active immunotherapy for prostate cancer)?

Also, besides the charts, are there any biotech companies with products/technologies that you do like?

Thanks, Ilene

jon said...

I was looking at your posts about cancer and found a good article about the same cancer info too...

God luck with it : )

bemusedly resources said...

Looking for national cancer institute information I came across this post. I totally agree with you and would feel the same way!

jon